Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve 1. To Consider and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals (formerly Trimurthi Limited) has informed BSE about a board meeting scheduled for 12 February 2026. The board will consider and approve the unaudited standalone financial results for the quarter ended 31 December 2025 along with the auditors' limited review report. Additionally, the board will consider allotment of equity shares on a preferential basis. The trading window for designated persons has been closed from 1 January 2026 until 48 hours after the board meeting concludes. The company is listed on BSE with scrip code 536565 and is based in Hyderabad, Telangana.
Shareholders should watch for the Q3 FY26 results announcement on or after 12 February 2026, which could move the stock. The preferential allotment of new equity shares will dilute existing shareholders' holdings — the size and pricing of the issue will be key details to look out for.